Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade is a standard treatment for non-small cell lung cancer (NSCLC).
• Current PD-1/PD-L1 blockade benefits a limited patient population, with many experiencing relapse or progression.
• Combination therapies are being explored to enhance efficacy and overcome resistance in NSCLC treatment.

Purpose of the Study:

• To review PD-1/PD-L1 blockade in combination with chemotherapy, targeted therapy, and immunotherapy for NSCLC.
• To elucidate the mechanisms by which these combinations regulate the cancer-immunity cycle.
• To provide a rationale for PD-1/PD-L1 blockade-based combination therapies and address associated challenges.

Main Methods:

• Literature review of studies on PD-1/PD-L1 blockade combined with various treatment modalities.
• Analysis of the impact on the cancer-immunity cycle.
• Discussion of clinical relevance and challenges.

Main Results:

• Combination therapies show potential to broaden patient response to PD-1/PD-L1 blockade.
• Mechanisms involve modulating key steps in the cancer-immunity cycle.
• Specific combinations may overcome or delay acquired resistance.

Conclusions:

• PD-1/PD-L1 blockade combined with chemotherapy, targeted therapy, or immunotherapy offers a promising strategy to improve NSCLC treatment.
• Understanding the cancer-immunity cycle provides a framework for rational combination therapy design.
• Further research is needed to optimize combination regimens and address challenges for broader clinical application.